Compare Gilead Sciences, Inc. (GILD) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lululemon Athletica Inc — how do they compare? Gilead Sciences, Inc. trades at $136.16 (market cap $163.51B), while Lululemon Athletica Inc trades at $118.62 (market cap $13.33B). The key difference: Gilead Sciences, Inc. is far larger — about 12.3× Lululemon Athletica Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| GILD | LULU | |
|---|---|---|
Market Cap | $163.51B | $13.33B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $233.31 |
52-Week Low | $108.22 | $105.43 |
Enterprise Value | $178.05B | $13.96B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lululemon trades at $119.05, up 1.47% with neutral technical indicators and mixed sentiment. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.69 beating expectations of $1.67. Revenue grew to $10.59B in 2025 with robust profitability metrics including 55.7% gross margin and 32.03% ROE. Recent developments include a $30M investment in nylon recycling startup Syntetica and resolution of board disputes with founder Chip Wilson.
The outlook remains cautiously optimistic with a consensus price target of $129.29 offering 8.6% upside potential. Key opportunities include strong brand positioning and consistent execution, while risks involve competitive pressures and recent controversies affecting consumer trust. Analyst consensus leans neutral with 40.85% buy ratings versus 53.52% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
